The PROFILE 1014 trial, a pivotal phase III clinical trial, compared the efficacy of crizotinib to standard chemotherapy in previously untreated ALK-positive advanced NSCLC patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.